Andros Pharmaceuticals Co (ROCO:6917) ROCE % : -22.28% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Andros Pharmaceuticals Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -22.28%.

Andros Pharmaceuticals Co ROCE % Historical Data

The historical data trend for Andros Pharmaceuticals Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co ROCE % Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-33.14

-23.67

-31.67

-19.74

-16.78

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-40.12	-23.48	-16.66	-16.31	-22.28

Andros Pharmaceuticals Co ROCE % Calculation

Andros Pharmaceuticals Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-67.697	/	( ( (329.597 - 19.679)	+	(529.146 - 31.97) )	/ 2 )
	=	-67.697	/	( (309.918	+	497.176)	/ 2 )
	=	-67.697	/	403.547
	=	-16.78 %

Andros Pharmaceuticals Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-86.984	/	( ( (301.678 - 17.989)	+	(529.146 - 31.97) )	/ 2 )
	=	-86.984	/	( ( 283.689	+	497.176 )	/ 2 )
	=	-86.984	/	390.4325
	=	-22.28 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Andros Pharmaceuticals Co (ROCO:6917) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Andros Pharmaceuticals Co ROCE % Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines